Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

AdvaMed, MDMA Take Issue With CMS’ New Tech Add-On Payment Policy

This article was originally published in The Gray Sheet

  • News

Executive Summary

CMS' proposed redefinition of "new" technologies contradicts Medicare statute, according to AdvaMed

You may also be interested in...



AdvaMed Provides CMS With New Technology Add-On Payment Wish List

AdvaMed is urging CMS to make its annual "town hall" meeting on new technology add-on payment submissions more interactive

AdvaMed Provides CMS With New Technology Add-On Payment Wish List

AdvaMed is urging CMS to make its annual "town hall" meeting on new technology add-on payment submissions more interactive

AdvaMed To Seek Legislative Fix To Ease New Tech Add-On Payment Criteria

CMS' discovery that Stryker Biotech (OP-1) has offered a comparable product to Medtronic's InFuse bone graft for tibia fractures since 2001 led the agency to reject the latter firm's new technology add-on application

Table

View full table

Related Content

Medtech Insight
Medtech Insight
Medtech Insight
Tags:
Latest Headlines

Second EU MDR Notified Body Designated In France

Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217

CDS Final Guidance Draws More Criticism, This Time From Congress

Alarming Rise Of Diabetes in Several US States, Study Shows

See All
UsernamePublicRestriction

Register

MT020336

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By